WASHINGTON, July 26 (Reuters) - A U.S. Food and Drug Administration panel on Thursday recommended two drugs for combating different forms of vision loss that can lead to blindness among a range of adults, including diabetics and the elderly.
The FDA advisory committee of outside experts gave its support to Swiss-based Roche Holding AG's Lucentis eye drug for treatment of diabetic macular edema and Belgium-based ThromboGenics' treatment for viteromacular adhesion, a condition that often develops with aging.
The recommendations will now be considered by FDA regulators as they decide whether to approve the two injectable drugs for sale in the United States.
The news emerged after the companies' shares had ended trading in Europe. Roche shares closed slightly higher at 168 Swiss francs, while ThromboGenics fell 4.82 percent to 23.30 euros.
The panel gave its blessing to both 0.3 milligram and 0.5 milligram doses of Roche's drug, known generically as ranibizumab, after reviewing clinical research showing it clearly helps diabetic patients who suffer from diabetic macular edema, or DME.
However, some panel members expressed concern about evidence linking higher doses of the drug to adverse events, including death.
Lucentis, which is made by Roche unit Genentech and administered by monthly injection, is already approved for two other eye ailments.
"The committee's recommendation is an important step towards improving the care of Americans with diabetic macular edema. If approved by the FDA, this will be the first major development for treating diabetic macular edema in more than 25 years," Genentech said in a statement.
The leading cause of vision loss among diabetics, DME occurs when leaking blood vessels in the eye cause swelling at the center of the retina. The result is a progressive blurring of images near the center of a patient's field of vision, and sometimes blindness.
About 75,000 new cases of DME are estimated to develop among Americans each year. Genentech says that about 560,000 in total are affected by the disease.
There are currently no FDA-approved drugs for DME. The condition is currently treated by laser surgery to stop blood vessels from leaking. The treatment can slow vision loss, but it rarely leads to vision improvement.
Lucentis is already approved to treat wet age-related macular degeneration - the leading cause of blindness among the elderly. It is also approved for macular edema following retinal vein occlusion (RVO), a swelling or thickening of the part of the retina responsible for central vision.
If approved for DME, Lucentis will likely compete with a highly promising drug being tested by Regeneron Pharmaceuticals Inc and Roche's own cancer drug, Avastin, which works in a similar manner as Lucentis.
Regeneron shares closed 5.3 percent higher at $135.64 on Nasdaq following the advisory panel's decision.
The same FDA committee later concluded that ThromboGenics' injectable drug, known generically as ocriplasmin, helped enough people in clinical trials to warrant a favorable review, despite evidence of adverse effects, including eye pain, swelling and blurred vision.
Several panel members recommended further studies to monitor safety and determine more fully the drug's effectiveness.
Vitreomacular adhesion often results from aging and can lead to visual impairment or blindness. But it currently can be treated only through surgery.
It occurs when vitreous gel detaches at the back of the eye but adheres to the retina as it pulls away, distorting vision and causing small breaks to develop in the macula, a portion of the retina that is important for central vision.
Ocriplasmin is ThromboGenics' main drug. The company has secured a deal to sell ocriplasmin in 40 countries outside the United States through Novartis AG's opthalmic division, Alcon.
ThromboGenics plans to market the product itself within the United States.
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.